Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ines Pires Da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille Lea Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen Kaur Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long
Institutions: Melanoma Institute Australia, The Netherlands Cancer Institute, Vanderbilt University Medical Center, Peter MacCallum Cancer Centre, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Centre Hospitalier Universitaire Vaudois, University Hospital Zurich, Austin Health, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen, Université Paris-Saclay, Institut Gustave Roussy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The Alfred Hospital, Alfred Health, SIB Swiss Institute of Bioinformatics, Université Paris Cité, Westmead Hospital, The University of Sydney, Royal North Shore Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3169350985